skip to content
  1. Home
  2. >
  3. Investment Q&A
You can view 3 more answers this month. Sign up for a free trial for unlimited access.

Investment Q&A

Not investment advice or solicitation to buy/sell securities. Do your own due diligence and/or consult an advisor.

Q: Really perturb with the performance,or should I said non-performance,of GUD especially with the recent downturn when the N.A. markets had rallied so much from the March lows.It delayed report of Q till June 26.Please comment & maybe have to wait till 6/26 when its results will include its big acquisition.Txs for u usual great advices & services
Read Answer Asked by Peter on June 08, 2020
Q: Hi 5iTeam,
Both of the above 2 ETFs are pretty well100% focused on health care with very similar make up (65% US, 35% non-US), why then there is such a big difference in dividend yield, Life pays 7.1% while XHC pays 1.05% in dividend.
Cheers,
Read Answer Asked by Harry on June 05, 2020
Q: Van Eck Vectors Biotech E.T.F. BBH (Nasdaq)
1. I rarely buy ETFs. When I do, I favor ones with less than 50 holdings. I am under the impression that an ETF with a large number of holdings is so diluted that you tend not to get as much upside/downside. Is this this approach favoring higher beta better or worse than one that ignores the number of holdings?
2. BBH has a relatively concentrated portfolio of 26 biotech businesses.
3. Your insight into BBH please? Substance only please; have already reviewed material including ETF.com, ETF Channel.
4. If you think others are better , please do suggest names. I have not researched IBB or XBB.
Read Answer Asked by Adam on June 05, 2020
Q: I’ve patiently held GUD for 4 years now without it doing much. Could you recommend 1 or 2 replacements from the Healthcare sector in the U.S. ?

I don’t understand the healthcare business myself, so I’m looking for a company with solid management that I can invest in, and then just forget about it for years to come.
Read Answer Asked by Andrew on June 04, 2020
Q: In view of the GBT acquisition, expected increase in revenues, what would be a fair price based on the industry average PE ratios, at the end of 2020 ? Do you think GUD will remain in the dog house for investors much longer ? I would have thought the GBT acquisition would have have changed investor sentiment, but clearly has not. What needs to happen to move the stock ?
Thanks
Read Answer Asked by Luc on June 01, 2020
Q: Hi,

What is your valued opinion of Kneat these days?
The last question on Nov 2019 indicated the sales valuation at 12x was concerning. Has that number come down enough for you to be more favourable as a spec buy.
They recently had another good quarter (Q1) with good % increases (albeit likely from a small base). They seem to be signing a number of contract wins last few quarters and I like that it is a SaaS based revenue model company.
Who might their other competitors be in this field? And any idea what their market penetration might be, for the competitors or for Kneat?
It would be for a spec buy and to initiate a 1/3 position.

Cheers,
Steve
Read Answer Asked by Stephen on June 01, 2020
Q: Thank you for the information on CloudMD, I accidently had it flagged as private, my follow-up question is, I was interested in the company due to the remote health services and digitizing the medical sector, I did well with a company in the past in this space but it was bought out and looking for another. I know Telus is in this space but very small compared to it's other business. Any suggestions?
Read Answer Asked by Tim on June 01, 2020
Looking for more? Sign up for a FREE 14 day trial! No credit card required

We invite you to sign up for a 14 day free trial of 5i Research!
Experience all the benefits and tools we have to offer; stock research, model portfolios, Q&A with our experts, and so much more. Join a community of like-minded investors today!